inactivated)
Sponsors
Aarhus University Hospital, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Cr2o B.V., Sanofi Vaccines US Inc., GlaxoSmithKline Biologicals
Conditions
COVID-19COVID-19 and fluHumanInfluenzaType 1 diabetes
Phase 2
INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED trial)
RecruitingCTIS2022-500906-17-01
Start: 2023-03-21Target: 100Updated: 2025-08-29
CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER
CompletedCTIS2024-514798-23-00
Start: 2024-10-02End: 2025-03-04Target: 120Updated: 2024-10-14
Phase 3
A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age
Not yet recruitingCTIS2026-526925-17-00
Target: 1500Updated: 2026-09-25
A phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mRNA- based seasonal influenza vaccine in older adults ≥65 years of age
Not yet recruitingCTIS2026-526682-14-00
Target: 12000Updated: 2026-09-25
A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine with Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
Not yet recruitingCTIS2026-526221-18-00
Target: 2735Updated: 2026-10-06